FibroGen (FGEN) Peer Comparison

$7.50

$-1.72 (-18.66%)

As on 05-Feb-2026 09:30EDT

Market cap

$39 Mln

Revenue (TTM)

$-118 Mln

P/E Ratio

--

P/B Ratio

53.8

Div. Yield

0 %

Edit

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Market cap ($ Mln)	39	15	5
Revenue ($ Mln)	-118	1	--
Net Profit ($ Mln)	215.65	-18.14	-5.00
Net Margin (%)	-182.61	-1,815.62	-113,076.32
RoE (%)	--	--	-232.24
Price to Earnings	--	--	--
Price-To-Book	53.83	7.72	1.13

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Operating Revenue	-118.09	1.00	0.00
Cost of Revenue	-20.39	17.76	0.01
Gross Profit	14.06	-48.29	0.00
Operating Expenses	26.33	81.64	5.07
Operating Profit (EBIT)	-124.04	-98.40	-5.07
Other Income	0.00	0.00	0.00
Profit before Tax	-131.27	-18.14	-5.00
Provision for Tax	-213.92	0.12	0.00
Profit after Tax (Net Income)	215.65	-18.14	-5.00
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Shareholder's Funds	-17.03	-0.56	4.25
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	83.56	2.03	0.74
Current Liabilities	35.97	32.90	1.10
Total Liabilities	214.53	86.69	3.02

Assets ($ Mln)

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Non-Current Assets	3.59	2.72	0.03
Current Assets	133.42	31.65	6.06
Total Assets	214.53	86.69	3.02
Total Debt*	19.47	2.50	0.00
Net Current Assets	97.45	-1.25	4.22

Cashflow ($ Mln)

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Cash From Operating Activities	-138.00	-84.31	-4.53
Cash Flow from Investing Activities	125.99	--	--
Cash from Financing Activities	-0.26	113.81	1.06
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
ROCE (%)	56.26	-486.39	-152.54
ROE (%)	22.14	-529.97	-232.24
ROA (%)	68.69	-13.30	-78.57
EBIT Margin (%)	109.06	-10,073.57	-114,018.08
Net Margin (%)	-182.61	-1,815.62	-113,076.32
Cash Profit Margin (%)	0.00	0.00	-25.56

Growth Ratios

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Revenue Growth (%)	-218.29	573.46	-75.26
EBIT Growth (%)	19.64	-9.05	3.26
Net Profit Growth (%)	277.07	90.32	-0.22
EPS Growth (%)	677.48	93.16	61.93
Book Value Growth (%)	93.05	-109.44	-74.09

Valuation Ratios

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Price / Earnings	-0.04	-1.11	-0.02
Price / Book Value	-0.01	2.06	0.08
Dividend Yield (%)	--	--	--
EV/EBITDA	-0.29	-0.39	0.37
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	0.00	-0.83	0.00
Current Ratio	3.71	0.96	5.49
Quick Ratio	3.60	0.96	5.49
Interest Coverage	-14.33	--	--

Operating Efficiency Ratios

	FibroGen (FGEN)	Applied Therapeutics (APLT)	Salarius Pharmaceuticals (SLRX)
Debtors to sales (%)	-0.10	1,666.97	0.00
Asset Turnover	-0.38	0.01	0.00
Receivable days	256.07	228.78	--
Inventory Days	524.84	24.60	--
Payable days	270.21	23.14	63,565.68
Cash Conversion Cycle	510.70	230.25	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly